The Food and Drug Administration has given Sorrento Therapeutics, Inc. located in San Diego approval to proceed with a phase one clinical trial of a new treatment.
COVI-GUARD (STI-1499) is for patients hospitalized with the coronavirus. Residents of Sorrento Valley under such conditions may be interested in becoming part of the clinical trial.
Preclinical studies of the treatment demonstrated that it was completely effective when used in a test environment of neutralizing the disease, and that it was able to prevent the infection of healthy cells. It was later evaluated in preclinical studies using multiple strains of the virus and was found effective against more contagious strains. Print shops are often hired to create materials with more information about such studies and their outcomes.
The effective dose used in hamsters was a projected dose of 160 mg in human patients. The phase one trail, however, will be using a dose of 200 mg per patient. STI-1499 is a highly potent treatment which may enable rapid scaling up of manufacturing operations.
Sorrento Therapeutics is a biopharmaceutical company focusing on the development of new therapies for the treatment of cancer.
The clinical trial is being designed so that it can be expanded rapidly and will be using sites in Brazil in order to supplement its trails in the United States. The expected completion date for the trial with final data collection is February of next year.
Get a Free Quote for Print
